Alembic Pharma gets rating reaffirmation from CARE for bank facilities

13 Mar 2012 Evaluate

Credit rating agency CARE has reaffirmed AA rating to Rs 22.06 crore long term bank facilities of Alembic Pharmaceuticals. The rating agency has also reaffirmed AA/A1+ rating to Rs 248 crore short term bank facilities of the company. Further, rating agency has reaffirmed AA rating to Rs 50 crore Non Convertible Debenture (NCD) of the company.

The ratings take into account the company’s impressive track record of over 100 years, the company’s comfortable financial risk profile and its dominant position in the macrolides segment in the domestic formulation market with established brands and successful diversification into fast-growing chronic segments through acquisition of non-oncology pharmaceutical business of Dabur.

Alembic Pharmaceuticals was incorporated in June 2010 after the demerger of core pharmaceutical business of erstwhile Alembic, one of the oldest pharmaceutical companies in India. APL is an integrated company having presence across the pharmaceutical value chain.

Alembic Pharma Share Price

1041.80 3.60 (0.35%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.